DE60207043D1 - Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese - Google Patents

Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese

Info

Publication number
DE60207043D1
DE60207043D1 DE60207043T DE60207043T DE60207043D1 DE 60207043 D1 DE60207043 D1 DE 60207043D1 DE 60207043 T DE60207043 T DE 60207043T DE 60207043 T DE60207043 T DE 60207043T DE 60207043 D1 DE60207043 D1 DE 60207043D1
Authority
DE
Germany
Prior art keywords
hrgp
angiogenesis
histidine
polypeptides
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60207043T
Other languages
English (en)
Other versions
DE60207043T2 (de
Inventor
Claesson Welsh
Helena Larsson
Anna-Karin Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoventus Project AB
Original Assignee
Innoventus Project AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innoventus Project AB filed Critical Innoventus Project AB
Application granted granted Critical
Publication of DE60207043D1 publication Critical patent/DE60207043D1/de
Publication of DE60207043T2 publication Critical patent/DE60207043T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE60207043T 2001-02-05 2002-02-04 Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese Expired - Fee Related DE60207043T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26650501P 2001-02-05 2001-02-05
US266505P 2001-02-05
PCT/IB2002/002425 WO2002076486A2 (en) 2001-02-05 2002-02-04 Histidine-rich glycoprotein

Publications (2)

Publication Number Publication Date
DE60207043D1 true DE60207043D1 (de) 2005-12-08
DE60207043T2 DE60207043T2 (de) 2006-07-13

Family

ID=23014841

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60207043T Expired - Fee Related DE60207043T2 (de) 2001-02-05 2002-02-04 Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese

Country Status (8)

Country Link
US (2) US7205392B2 (de)
EP (1) EP1357930B1 (de)
JP (1) JP2004527242A (de)
AT (1) ATE308335T1 (de)
CA (1) CA2436340A1 (de)
DE (1) DE60207043T2 (de)
ES (1) ES2252461T3 (de)
WO (1) WO2002076486A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357930B1 (de) 2001-02-05 2005-11-02 Innoventus Project AB Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
JP2005528879A (ja) * 2001-02-14 2005-09-29 アテニュオン， エルエルシー 抗脈管形成剤および抗腫瘍剤としてのヒスチジンプロリンリッチ糖タンパク質（ｈｐｒｇ）
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
SE0301988D0 (sv) * 2003-07-07 2003-07-07 Innoventus Project Ab Active subfragment of an endogenous peptide
CN102895663A (zh) * 2004-04-14 2013-01-30 健泰科生物技术公司 含有用于调节血管发育的egfl7拮抗剂的组合物及方法
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2553464A4 (de) * 2010-04-01 2014-04-02 Karolinska Inst Innovations Ab Befruchtungsprognose und -förderung
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
US9504731B2 (en) 2012-06-06 2016-11-29 National University Corporation Okayama University Therapeutic agent, treatment method and inspection method for diseases caused by activation of neutrophils
US9696321B2 (en) 2012-06-06 2017-07-04 National University Corporation Okayama University Therapeutic agent, method of treatment and method for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused or accompanied by neutrophil activation
BR112018000054A2 (pt) 2015-07-02 2018-09-04 Otsuka Pharmaceutical Co., Ltd. composições farmacêuticas liofilizadas
SG11202000932XA (en) 2017-08-03 2020-02-27 Otsuka Pharma Co Ltd Drug compound and purification methods thereof
US20210198317A1 (en) 2018-05-31 2021-07-01 National University Corporation Okayama University Reactive oxygen production inhibitor and/or scavenging promoter
CN112512547A (zh) 2018-06-28 2021-03-16 国立大学法人冈山大学 嗜中性粒细胞吞噬能力增强剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5133866A (en) 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
JPH0753757B2 (ja) * 1988-08-12 1995-06-07 寳酒造株式会社 モノクローナル抗体及びその使用方法
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
CA2406882A1 (en) 1999-10-01 2001-04-12 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting upa and upar
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
AU2001227679A1 (en) 2000-02-25 2001-09-03 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
WO2002014369A2 (en) 2000-07-24 2002-02-21 Attenuon, Llc Human kininogen d5 domain polypeptides and their use
WO2002069885A2 (en) 2001-01-19 2002-09-12 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods for treating brain tumors and other diseases
EP1357930B1 (de) 2001-02-05 2005-11-02 Innoventus Project AB Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
JP2005528879A (ja) 2001-02-14 2005-09-29 アテニュオン， エルエルシー 抗脈管形成剤および抗腫瘍剤としてのヒスチジンプロリンリッチ糖タンパク質（ｈｐｒｇ）

Also Published As

Publication number Publication date
CA2436340A1 (en) 2002-10-03
EP1357930A2 (de) 2003-11-05
WO2002076486A3 (en) 2003-04-17
US7205392B2 (en) 2007-04-17
ATE308335T1 (de) 2005-11-15
US7563765B2 (en) 2009-07-21
ES2252461T3 (es) 2006-05-16
DE60207043T2 (de) 2006-07-13
EP1357930B1 (de) 2005-11-02
US20050042201A1 (en) 2005-02-24
WO2002076486A2 (en) 2002-10-03
US20020165131A1 (en) 2002-11-07
JP2004527242A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
DE60207043D1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
HK1088840A1 (en) Stable analogs of glp-1 glp-1
DE69936105D1 (de) Menschliche tslp nukleinsäuren und polypeptide
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
DE69926480D1 (de) Acpl dna und polypeptide
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
DK1461073T3 (da) Peptidagonister til prostataspecifikt antigen og anvendelser heraf
NO20063026L (no) Antistoffer
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
HRP20050024A2 (en) Pegylated t20 polypeptide
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
CY1107594T1 (el) DNA ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ IL-1η
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
ATE321853T1 (de) Humanische pellino-polypeptide
DE60214676D1 (de) Hochaffine antagonisten der elr-cxc chemokine
DE60219215D1 (de) Prionen-bindende peptidsequenzen
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
MXPA04004564A (es) Genes que codifican receptores acoplados a proteinas g y metodos de uso de los mismos.
ATE442444T1 (de) Glykosylphosphatidylinositolhaltige polypeptide
NZ503852A (en) Death associated kinase containing ankyrin repeats (DAKAR)
ATE443715T1 (de) Polypeptide aus haemophilus influenza
DE60039303D1 (de) Immunogene polypeptide aus moraxella catarrhalis und deren verwendungen
DE10394174D2 (de) Peptide mit hohem Cysteingehalt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee